Open Access

VIEWPOINT

Mesenchymal stem cells and cell-free preparations for treating atopic dermatitis

TRINIDAD MONTERO-VILCHEZ^1,2,*, MANUEL SANCHEZ-DIAZ^1,2, CAROLINA MONTERO-VILCHEZ³, ALVARO SIERRA-SANCHEZ², SALVADOR ARIAS-SANTIAGO^1,2,4

1 Dermatology Department, Virgen de las Nieves University Hospital, Granada, Spain
2 Instituto de Investigación Biosanitaria Granada, Granada, Spain
3 Pharmacy Department, Virgen de las Nieves University Hospital, Granada, Spain
4 Dermatology Department, Faculty of Medicine, University of Granada, Granada, Spain

* Corresponding Author: TRINIDAD MONTERO-VILCHEZ. Email:

BIOCELL 2022, 46(11), 2363-2367. https://doi.org/10.32604/biocell.2022.021399

Received 12 January 2022; Accepted 11 April 2022; Issue published 07 July 2022

Abstract

Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease caused by an interaction between genetic, immune and epidermal barrier factors. Several treatments can be used to treat this disease but there are patients that do not respond to actual drugs. So, there is a need to develop effective therapies for AD. Mesenchymal stem cells (MSCs) are non-hematopoietic multipotent adult progenitor cells with immunomodulatory power and self-regenerating capacity to repair tissue damage, so they could be a potential effective treatment for AD. MSCs-Conditioned Medium (CM) and MSCs-exosomes are cell-free preparation with molecules secreted by stem cells that could be also beneficial for AD. This viewpoint reviews the actual development of MSCs, MSCs-CM and MSCs-exosomes for treating patients with AD.

---

Keywords

---